NCT03126773View on ClinicalTrials.gov

A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia

CompletedOBSERVATIONAL
Enrollment

1,570

Participants

Timeline

Start Date

May 2, 2017

Primary Completion Date

November 30, 2019

Study Completion Date

June 18, 2020

Conditions
Menopause
Interventions
DRUG

BAY86-4891

Drospirenone 0.25 mg + estradiol hemihydrate 0.5 mg (Angeliq Micro, G03FA17).Dosage form is one tablet a day.

Trial Locations (1)

Unknown

Many locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY